Showing results (571-580 of 776) with videos related to
Sort By:
Pageof 78
Journal of the American Academy of Dermatology|May 14, 2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialBruce Strober, Carle Paul, Andrew Blauvelt, et al.Experimental Dermatology|June 12, 2026
Vagus Nerve Stimulation Reduces Cutaneous Inflammation and Proinflammatory Cytokines in Murine Models of Psoriasis and Atopic DermatitisWilliam J Nahm, Ki-Joong Kim, Eui Namgung, et al.Clinical, Cosmetic and Investigational Dermatology|November 2, 2016
The psychosocial impact of acne, vitiligo, and psoriasis: a reviewCatherine M Nguyen, Kourosh Beroukhim, Melissa J Danesh, et al.Journal of Medical Economics|June 5, 2019
Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI)Louis S Matza, John E Brazier, Katie D Stewart, et al.The New England Journal of Medicine|March 30, 2012
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasisKim A Papp, Craig Leonardi, Alan Menter, et al.Journal of the American Academy of Dermatology|January 30, 2013
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisAlexa B Kimball, David Pariser, Paul S Yamauchi, et al.Molecular Biology of the Cell|January 17, 2014
Critical roles for multiple formins during cardiac myofibril development and repairMichelle Rosado, Cynthia F Barber, Cristina Berciu, et al.The Journal of Pharmacology and Experimental Therapeutics|June 2, 2012
Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporterAlan Menter, Breck Thrash, Christina Cherian, et al.European Journal of Pediatrics|January 22, 2022
Review of the holistic management of pediatric atopic dermatitisArmaan Guraya, Karan Pandher, Caroline L Porter, et al.The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.Pageof 78